Merck & Co., Inc. (NYSE:MRK) Stock Price Breaks Above 50-Day Moving Average After Analyst Downgrade

Merck & Co., Inc. (NYSE:MRK) crossed above its 50-day moving average during trading on Friday after JPMorgan Chase & Co. raised their price target on the stock from $165.00 to $175.00. The stock has a 50-day moving average of $146.90 and traded as high as $151.35. JPMorgan Chase & Co. currently has an overweight rating on the stock. Merck & Co., Inc. shares last traded at $149.75, with a volume of 12,341,136 shares.

Several other analysts also recently commented on MRK. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research note on Wednesday, August 12th. Cantor Fitzgerald boosted their target price on Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Wells Fargo & Company upped their price target on Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, September 4th. Finally, TD Cowen increased their price target on Merck & Co., Inc. from $137.00 to $155.00 and gave the stock a “hold” rating in a report on Wednesday, September 23rd. Seventeen analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $153.36.

Insider Activity

In related news, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the sale, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 over the last ninety days. 0.17% of the stock is currently owned by company insiders.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Round Rock Advisors LLC lifted its position in shares of Merck & Co., Inc. by 0.7% during the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after acquiring an additional 66 shares during the period. Cypress Wealth Services LLC boosted its stake in shares of Merck & Co., Inc. by 0.5% during the 3rd quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock worth $1,960,000 after acquiring an additional 69 shares in the last quarter. Code Waechter LLC boosted its stake in shares of Merck & Co., Inc. by 3.4% during the 3rd quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock worth $317,000 after acquiring an additional 71 shares in the last quarter. Cascade Financial Partners LLC grew its holdings in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after acquiring an additional 80 shares during the period. Finally, Somerset Trust Co grew its holdings in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after acquiring an additional 81 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 2.3%

The firm has a market cap of $369.46 billion, a price-to-earnings ratio of 154.38, a PEG ratio of 6.38 and a beta of 0.21. The business has a fifty day moving average of $146.90 and a two-hundred day moving average of $126.69. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.40. The firm had revenue of $18.09 billion during the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.56% and a net margin of 3.64%. Merck & Co., Inc.’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.58 earnings per share. As a group, equities analysts expect that Merck & Co., Inc. will post 2.80 earnings per share for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.